Baicalein inhibits osteosarcoma cell proliferation and invasion through the miR‑183/Ezrin pathway

Zhang,Jian; Yang,Wei; Zhou,You‑Bing; Xiang,Yong‑Xiao; Wang,Lu‑Shan; Hu,Wen‑Kai; Wang,Wen‑Jun

doi:10.3892/mmr.2018.9036

Baicalein inhibits osteosarcoma cell proliferation and invasion through the miR‑183/Ezrin pathway

Authors:
- Jian Zhang
- Wei Yang
- You‑Bing Zhou
- Yong‑Xiao Xiang
- Lu‑Shan Wang
- Wen‑Kai Hu
- Wen‑Jun Wang
View Affiliations

Affiliations: Department of Hand Microsurgery, The First Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China, Department of Spine Surgery, The First Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China
Published online on: May 17, 2018 https://doi.org/10.3892/mmr.2018.9036
Pages: 1104-1112

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS), a common and primary malignant bone tumor, is characterized by highly aggressive potency. Baicalein, a bioactive flavone isolated from Scutellaria baicalensis Georgi, has been shown to inhibit the progression of numerous tumors, including OS. However, the mechanisms by which baicalein protects against OS are still largely unknown. The results of the present study showed that administration of baicalein significantly inhibited the proliferation, migration and invasion and promoted apoptosis in MG‑63 and Saos‑2 cells. Ezrin was identified as a target gene of microRNA (miR)‑183. MG‑63 and Saos‑2 cells treated with baicalein exhibited increased miR‑183 levels and decreased Ezrin expression. Importantly, miR‑183 inhibition and Ezrin overexpression abolished the effects of baicalein on MG‑63 and Saos‑2 cell proliferation, migration, invasion and apoptosis. Taken together, these findings suggest that baicalein inhibits the proliferation, migration and invasion and induces apoptosis in OS cells by activating the miR‑183/Ezrin pathway, revealing a novel mechanism underlying anti‑OS effects of baicalein.

View Figures

View References

1	Li J, Yang Z, Li Y, Xia J, Li D, Li H, Ren M, Liao Y, Yu S, Chen Y, et al: Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment. Oncotarget. 7:44763–44778. 2016.PubMed/NCBI
2	Zhang J, Yan YG, Wang C, Zhang SJ, Yu XH and Wang WJ: MicroRNAs in osteosarcoma. Clin Chim Acta. 444:9–17. 2015. View Article : Google Scholar : PubMed/NCBI
3	Zhou RT, He M, Yu Z, Liang Y, Nie Y, Tai S and Teng CB: Baicalein inhibits pancreatic cancer cell proliferation and invasion via suppression of NEDD9 expression and its downstream Akt and ERK signaling pathways. Oncotarget. 8:56351–56363. 2017.PubMed/NCBI
4	Liu X and Liu S, Chen J, He L, Meng X and Liu S: Baicalein suppresses the proliferation of acute T-lymphoblastic leukemia Jurkat cells by inhibiting the Wnt/β-catenin signaling. Ann Hematol. 95:1787–1793. 2016. View Article : Google Scholar : PubMed/NCBI
5	Wei N, Wei Y, Li B and Pang L: Baicalein promotes neuronal and behavioral recovery after intracerebral hemorrhage via suppressing apoptosis, Oxidative stress and neuroinflammation. Neurochem Res. 42:1345–1353. 2017. View Article : Google Scholar : PubMed/NCBI
6	Ye H, Zhang Y, Wang Y, Xia J, Mao X and Yu X: The restraining effect of baicalein and U0126 on human cervical cancer cell line HeLa. Mol Med Rep. 16:957–963. 2017. View Article : Google Scholar : PubMed/NCBI
7	Chai Y, Xu J and Yan B: The anti-metastatic effect of baicalein on colorectal cancer. Oncol Rep. 37:2317–2323. 2017. View Article : Google Scholar : PubMed/NCBI
8	Choi EO, Park C, Hwang HJ, Hong SH, Kim GY, Cho EJ, Kim WJ and Choi YH: Baicalein induces apoptosis via ROS-dependent activation of caspases in human bladder cancer 5637 cells. Int J Oncol. 49:1009–1018. 2016. View Article : Google Scholar : PubMed/NCBI
9	Ma X, Yan W, Dai Z, Gao X, Ma Y, Xu Q, Jiang J and Zhang S: Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway. Drug Des Devel Ther. 10:1419–1441. 2016. View Article : Google Scholar : PubMed/NCBI
10	Palmini G, Marini F and Brandi ML: What is new in the miRNA world regarding osteosarcoma and chondrosarcoma? Molecules. 22:pii: E417. 2017. View Article : Google Scholar : PubMed/NCBI
11	Zoni E and van der Pluijm G: The role of microRNAs in bone metastasis. J Bone Oncol. 5:104–108. 2016. View Article : Google Scholar : PubMed/NCBI
12	Cao LL, Xie JW, Lin Y, Zheng CH, Li P, Wang JB, Lin JX, Lu J, Chen QY and Huang CM: miR-183 inhibits invasion of gastric cancer by targeting Ezrin. Int J Clin Exp Pathol. 7:5582–5594. 2014.PubMed/NCBI
13	Li M, Feng YM and Fang SQ: Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer. Braz J Med Biol Res. 50:e53562017. View Article : Google Scholar : PubMed/NCBI
14	Kong J, Li Y, Liu S, Jin H, Shang Y, Quan C, Li Y and Lin Z: High expression of ezrin predicts poor prognosis in uterine cervical cancer. BMC Cancer. 13:5202013. View Article : Google Scholar : PubMed/NCBI
15	Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang X and Wang L: Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol. 180:2440–2451. 2012. View Article : Google Scholar : PubMed/NCBI
16	Zhang J, Zuo J, Lei M, Wu S, Zang X and Zhang C: Ezrin promotes invasion and migration of the MG63 osteosarcoma cell. Chin Med J (Engl). 127:1954–1959. 2014.PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Kushlinskii NE, Fridman MV and Braga EA: Molecular mechanisms and microRNAs in osteosarcoma pathogenesis. Biochemistry (Mosc). 81:315–328. 2016. View Article : Google Scholar : PubMed/NCBI
19	Anderson ME: Update on survival in osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
20	Gao Y, Snyder SA, Smith JN and Chen YC: Anticancer properties of baicalein: A review. Med Chem Res. 25:1515–1523. 2016. View Article : Google Scholar : PubMed/NCBI
21	Dinda B, Dinda S, DasSharma S, Banik R, Chakraborty A and Dinda M: Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders. Eur J Med Chem. 131:68–80. 2017. View Article : Google Scholar : PubMed/NCBI
22	Chung H, Choi HS, Seo EK, Kang DH and Oh ES: Baicalin and baicalein inhibit transforming growth factor-β1-mediated epithelial-mesenchymal transition in human breast epithelial cells. Biochem Biophys Res Commun. 458:707–713. 2015. View Article : Google Scholar : PubMed/NCBI
23	Dai G, Zheng D, Wang Q, Yang J, Liu G, Song Q, Sun X, Tao C, Hu Q, Gao T, et al: Baicalein inhibits progression of osteosarcoma cells through inactivation of the Wnt/β-catenin signaling pathway. Oncotarget. 8:86098–86116. 2017. View Article : Google Scholar : PubMed/NCBI
24	He N and Zhang Z: Baicalein suppresses the viability of MG-63 osteosarcoma cells through inhibiting c-MYC expression via Wnt signaling pathway. Mol Cell Biochem. 405:187–196. 2015. View Article : Google Scholar : PubMed/NCBI
25	Ye F, Wang H, Zhang L, Zou Y, Han H and Huang J: Baicalein induces human osteosarcoma cell line MG-63 apoptosis via ROS-induced BNIP3 expression. Tumour Biol. 36:4731–4740. 2015. View Article : Google Scholar : PubMed/NCBI
26	Pal MK, Jaiswar SP, Dwivedi VN, Tripathi AK, Dwivedi A and Sankhwar P: MicroRNA: A new and promising potential biomarker for diagnosis and prognosis of ovarian cancer. Cancer Biol Med. 12:328–341. 2015.PubMed/NCBI
27	Taylor MA and Schiemann WP: Therapeutic opportunities for targeting microRNAs in cancer. Mol Cell Ther. 2:1–13. 2014. View Article : Google Scholar : PubMed/NCBI
28	Nugent M: microRNA and bone cancer. Adv Exp Med Biol. 889:201–230. 2015. View Article : Google Scholar : PubMed/NCBI
29	Zhang QH, Sun HM, Zheng RZ, Li YC, Zhang Q, Cheng P, Tang ZH and Huang F: Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues. Gene. 527:26–32. 2013. View Article : Google Scholar : PubMed/NCBI
30	Mu Y, Zhang H, Che L and Li K: Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma. Med Oncol. 31:8212014. View Article : Google Scholar : PubMed/NCBI
31	Zhao H, Guo M, Zhao G, Ma Q, Ma B, Qiu X and Fan Q: miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells. Int J Mol Med. 30:1013–1020. 2012. View Article : Google Scholar : PubMed/NCBI
32	Abdou AG, Kandil M, Asaad NY, Dawoud MM, Shahin AA and Eldayem Abd AF: The prognostic role of Ezrin and HER2/neu expression in osteosarcoma. Appl Immunohistochem Mol Morphol. 24:355–363. 2016. View Article : Google Scholar : PubMed/NCBI
33	Zhao DH, Zhu J, Wang WB, Dong F, Zhang Q, Fan HW, Zhang JZ and Wang YM: Correlations of ezrin expression with pathological characteristics and prognosis of osteosarcoma: A meta-analysis. ScientificWorldJournal. 2014:8375432014. View Article : Google Scholar : PubMed/NCBI